Company: OSRH
Filing Date: 2025-01-24
Form Type: S-4/A
Source: 0001213900-25-006139
Chunk: 640

Company: OSR Holdings, Inc.
Filing Date: 2025-01-24
Form: S-4/A
Chunk 640
---
:----|:--------------------------------------|:----|------------:|:----|:---------|:----|:------------|:-------------------|:----|:--|:----|-----------:|:----|:--|:----|------------:|:----|:--|:----|------------:|
|                      |     |                                       |     |             |     |          |     |             | Non-cash movements |     |   |     |            |     |   |     |             |     |   |     |             |
| Beginning            |     |                                       |     |             |     | Cashflow |     |             | Interest           
 expense            |     |   |     |     Others |     |   |     |      Ending |     |   |     |             |
| Lease liabilities    |     | ₩                                     |     | 374,446,179 |     | ₩        |     | (83,212,151 | )                  |     | ₩ |     | 11,251,393 |     | ₩ |     | 164,920,724 |     | ₩ |     | 467,406,145 |

33. Operating Segments For business management purposes of the Consolidated Entity, sales consist of pharmaceutical manufacturing and medical device distribution, considered as a single operating division. There are no external customers that account for more than 10% of sales for the reporting period.

F-87

| Shinhan Accounting Corporation       
 8th FL, 8, Uisadang-daero            
 Yeongdeungpo-gu, Seoul, 07236, Korea 
 Telephone: 82-2-782-9940             
 Telefax: 82-2-782-9941               
 www.rsm.global/korea                 |

Report of Independent Registered Public Accounting Firm To the Shareholders and Board of Directors of
OSR Holdings Co., Ltd. Opinion on the Financial Statements We have audited the accompanying consolidated statements of financial position of OSR Holdings Co., Ltd. and its subsidiaries (the “Company”) as of December 31, 2023 and 2022, and the related consolidated statement of comprehensive income, changes in equity and cash flows for each of the years in the three -yearperiod ended December 31, 2023, and the related notes (collectively, the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects